CLINICAL_TRIALS
trial_result
· 2016-06-23
Clinical Trial Update: PK and PD Study of Natalizumab in Pediatric Subjects With RRMS [Phase 1]
Summary
A Phase 1 pharmacokinetic/pharmacodynamic study of natalizumab in pediatric relapsing-remitting multiple sclerosis has completed.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Biogen | Conditions: Relapsing-Remitting Multiple Sclerosis | Phase 1 | Status: COMPLETED